Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?
BACKGROUND: Biochemical testing for pheochromocytoma by measurement of fractionated plasma metanephrines is limited by false positive rates of up to 18% in people without known genetic predisposition to the disease. The plasma normetanephrine fraction is responsible for most false positives and plasma normetanephrine increases with age. The objective of this study was to determine if we could improve the specificity of fractionated plasma measurements, by statistically adjusting for age. METHODS: An age-adjusted metanephrine score was derived using logistic regression from 343 subjects (including 33 people with pheochromocytoma) who underwent fractionated plasma metanephrine measurements as part of investigations for suspected pheochromocytoma at Mayo Clinic Rochester (derivation set). The performance of the age-adjusted score was validated in a dataset of 158 subjects (including patients 23 with pheochromocytoma) that underwent measurements of fractionated plasma metanephrines at Mayo Clinic the following year (validation dataset). None of the participants in the validation dataset had known genetic predisposition to pheochromocytoma. RESULTS: The sensitivity of the age-adjusted metanephrine score was the same as that of traditional interpretation of fractionated plasma metanephrine measurements, yielding a sensitivity of 100% (23/23, 95% confidence interval [CI] 85.7%, 100%). However, the false positive rate with traditional interpretation of fractionated plasma metanephrine measurements was 16.3% (22/135, 95% CI, 11.0%, 23.4%) and that of the age-adjusted score was significantly lower at 3.0% (4/135, 95% CI, 1.2%, 7.4%) (p < 0.001 using McNemar's test). CONCLUSION: An adjustment for age in the interpretation of results of fractionated plasma metanephrines may significantly decrease false positives when using this test to exclude sporadic pheochromocytoma. Such improvements in false positive rate may result in savings of expenditures related to confirmatory imaging.
Sawka
Anna M
AM
Department of Internal Medicine, St, Joseph's Healthcare, Hamilton, Ontario, L8N 4A6, Canada. sawkaam@yahoo.com.
Thabane
Lehana
L
Gafni
Amiram
A
Levine
Mitchell
M
Young
William F
WF
Clin Chem. 1993 Jan;39(1):97-103
8419068
J Clin Endocrinol Metab. 2003 Feb;88(2):553-8
12574179
Baillieres Clin Endocrinol Metab. 1993 Apr;7(2):509-44
8489489
Endocr Rev. 1994 Jun;15(3):356-68
8076587
Trends Endocrinol Metab. 1993 May-Jun;4(4):122-7
18407145
Clin Chem. 2001 Jun;47(6):1061-7
11375292
JAMA. 2002 Mar 20;287(11):1427-34
11903030
Eur J Clin Invest. 2003 Jun;33(6):480-7
12795644
Mayo Clin Proc. 1995 Aug;70(8):757-65
7630214
J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):62-72
11821644
Endocrinol Metab Clin North Am. 2000 Mar;29(1):159-85, x
10732270
Baillieres Clin Endocrinol Metab. 1993 Apr;7(2):491-507
8489488
J Clin Endocrinol Metab. 2003 Jun;88(6):2656-66
12788870
BMC Endocr Disord. 2004 Jun 29;4(1):2
15225350
Cancer Treat Res. 1997;89:239-61
9204196
Braz J Med Biol Res. 2000 Oct;33(10):1157-69
11004716
J Clin Endocrinol Metab. 2004 Jun;89(6):2859-66
15181069